[{"id":"c0a06349-a221-453f-bcd3-a07338de124e","acronym":"MATISSE","url":"https://clinicaltrials.gov/study/NCT05742607","created_at":"2023-02-24T16:01:14.327Z","updated_at":"2024-07-02T16:35:14.384Z","phase":"Phase 2","brief_title":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","source_id_and_acronym":"NCT05742607 - MATISSE","lead_sponsor":"Innate Pharma","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-15"}]